LOGIN  |  REGISTER
Cue Biopharma
C4 Therapeutics

Superlatus Announces Planned Expansion into Pet Food Market

September 07, 2023 | Last Trade: US$ 8.00 0.00 0.00

TAMPA, FL, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Superlatus, Inc., a food technology and distribution company that recently merged with a subsidiary of pharmaceutical exchange platform provider TRxADE HEALTH, Inc. (Nasdaq: MEDS), today announced it plans to enter the worldwide pet foods market, specializing in plant-based, high-protein foods and snacks.

Superlatus will launch the expansion with assorted flavors of baked plant-based treats, then intends to follow with a full offering of veterinarian formulated, plant-based, high-protein full meal offerings. All products will feature reduced calorie and saturated fat content compared to traditional animal-based pet meals and treats and will utilize plant-based ingredients from strategic supply partners.

The company is currently in discussion with several major national pet food chains to participate as a launch partner for the products, said Superlatus.

All the new treat offerings will utilize an advanced food extrusion technology from Sapientia Technology, LLC, a wholly owned subsidiary of Superlatus. This technology, developed by well-known food scientist Dr. Gino Bortone, enables Superlatus to create dense, protein rich, plant-based dog treats.

“We are excited to enter this market,” stated Superlatus CEO Tim Alford. “According to a broad array of established data sources, the plant-based segment of the pet food industry is growing significantly faster than the traditional animal-based segment.”

One such source, Future Market Insights (FMI), recently announced that, in 2023, the vegan dog food market was estimated to be worth $13.58 billion and is anticipated to register a CAGR of 7 percent for the next 10 years, reaching a value of $ 26.35 billion by 2033.

In contrast, reported FMI, the conventional, animal-based dog food market, which has a current value of $68.27 billion, is anticipated to expand with a CAGR of only 4.35 percent to 2033. This slower rate of projected growth, added FMI, is attributable primarily to both widespread consumer awareness of the health advantages of vegan pet foods as well as the increased numbers of online sales channels available for such foods.

“As a company with a core mission to create a healthier and more sustainable future for our planet, we are extremely proud to offer consumers these better-for-your-pet food products,” continued Mr. Alford. “We believe they will rank among the healthiest and most delicious products our pets can eat.

“We anticipate the initial line of vegan pet treats will likely be available by Q1 2024 with the vegan full meal offerings hitting the market by later in 2024.”

About Superlatus, Inc.

Superlatus is a diversified food technology company with distribution capabilities. We scale food innovation and transformational change to our food systems to optimize food security and population health via innovative CPG products, agritech, foodtech, plant-based proteins and alt-proteins. We provide industry-leading processing and forming technologies that create high nutrition, high taste, and textured foods. Our management team consists of world-class food executives with an unparalleled understanding of technology and taste. For more information on Superlatus, please visit Superlatus’ website at https://www.superlatusfoods.com.

About TRxADE HEALTH, INC.

TRxADE HEALTH (NASDAQ: MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. TRxADE HEALTH ( NASDAQ: MEDS) plans to exit its legacy businesses and focus on the Superlatus foods business after its next special meeting of shareholders. For more information on TRxADE HEALTH, please visit the Company’s IR website at investors.trxadegroup.com.

Forward-Looking Statements

This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; risks that our food products will not achieve expected market acceptance; the outcome of any current legal proceedings or future legal proceedings that may be instituted against the parties or others; and those risks detailed in TRxADE’s most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. The TRxADE undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

Investor Contact:
Skyline Corporate Communications Group, LLC
Scott Powell, President
One Rockefeller Plaza, 11th Floor
New York, NY 10020
Office: (646) 893-5835
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

C4 Therapeutics

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB